Corrigan Owen I, Li Xue
School of Pharmacy and Pharmaceutical Sciences, University of Dublin, Trinity College, Dublin, Ireland.
Eur J Pharm Sci. 2009 Jun 28;37(3-4):477-85. doi: 10.1016/j.ejps.2009.04.004. Epub 2009 Apr 18.
The objective of this work was to investigate the mechanism of release of active pharmaceutical ingredients (APIs) both small molecules (ketoprofen, indomethacin, coumarin-6) and macromolecules (human serum albumin, ovalbumin), from PLGA (50:50) nanoparticulates (400-700nm), having drug loadings less than 10%. The nanoparticulates were prepared by emulsification/solvent evaporation methods and release determined in phosphate buffer pH 7.4 at 37 degrees C. The release profiles exhibited an initial burst release phase, a slower lag phase and a second increased release rate phase. The profiles were consistent with a model in which the first phase of the release reflects diffusion controlled dissolution of drug accessible to the solid/dissolution medium interface and the second phase reflects release of drug entrapped in the polymer, the release of which was dependent on the bulk degradation of the polymer. The burst phase tended to increase with increase in API loading and solubility. The polymer erosion related parameters also indicated that increased drug loading accelerated this phase of API release. Small acidic hydrophobic actives such as ketoprofen and indomethacin had a much greater effect on these parameters than the larger hydrophilic more neutral proteins, HSA and ovalbumin.
这项工作的目的是研究活性药物成分(API)从载药量低于10%的PLGA(50:50)纳米颗粒(400 - 700nm)中的释放机制,这些活性药物成分包括小分子(酮洛芬、吲哚美辛、香豆素 - 6)和大分子(人血清白蛋白、卵清蛋白)。纳米颗粒通过乳化/溶剂蒸发法制备,并在37℃的pH 7.4磷酸盐缓冲液中测定释放情况。释放曲线呈现出一个初始突释阶段、一个较慢的滞后阶段和一个第二阶段的释放速率增加阶段。这些曲线与一个模型相符,在该模型中,释放的第一阶段反映了固体/溶解介质界面处可及药物的扩散控制溶解,而第二阶段反映了包封在聚合物中的药物的释放,其释放取决于聚合物的整体降解。突释阶段倾向于随着API载药量和溶解度的增加而增加。与聚合物侵蚀相关的参数也表明,增加药物载药量会加速API释放的这一阶段。与较大的亲水性更强的中性蛋白质(人血清白蛋白和卵清蛋白)相比,酮洛芬和吲哚美辛等小的酸性疏水性活性成分对这些参数的影响要大得多。